Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: Preliminary results of an ongoing phase I trial.
Publication
, Journal Article
Kurtzberg, J; Keating, MJ; Plunkett, W; Gandhi, V; Gold, S; Reese, M; Elion, G; Mitchell, B
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 1, 1996
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 1, 1996
Volume
14
Issue
5
Start / End Page
2022 / 2022
Publisher
W B SAUNDERS CO
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kurtzberg, J., Keating, M. J., Plunkett, W., Gandhi, V., Gold, S., Reese, M., … Mitchell, B. (1996). Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: Preliminary results of an ongoing phase I trial. JOURNAL OF CLINICAL ONCOLOGY, 14(5), 2022–2022.
Kurtzberg, J., M. J. Keating, W. Plunkett, V. Gandhi, S. Gold, M. Reese, G. Elion, and B. Mitchell. “Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: Preliminary results of an ongoing phase I trial.” JOURNAL OF CLINICAL ONCOLOGY 14, no. 5 (May 1, 1996): 2022–2022.
Kurtzberg J, Keating MJ, Plunkett W, Gandhi V, Gold S, Reese M, et al. Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: Preliminary results of an ongoing phase I trial. JOURNAL OF CLINICAL ONCOLOGY. 1996 May 1;14(5):2022–2022.
Kurtzberg, J., et al. “Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: Preliminary results of an ongoing phase I trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 14, no. 5, W B SAUNDERS CO, May 1996, pp. 2022–2022.
Kurtzberg J, Keating MJ, Plunkett W, Gandhi V, Gold S, Reese M, Elion G, Mitchell B. Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: Preliminary results of an ongoing phase I trial. JOURNAL OF CLINICAL ONCOLOGY. W B SAUNDERS CO; 1996 May 1;14(5):2022–2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 1, 1996
Volume
14
Issue
5
Start / End Page
2022 / 2022
Publisher
W B SAUNDERS CO
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences